13th Edition of International Conference on Neurology and Brain Disorders
October 19-21, 2026
Wilsons Disease
Wilson's Disease (also known as hepatolenticular degeneration) is an inherited disorder of copper metabolism that affects multiple organs including the liver, brain, and eyes. It is caused by a mutation of the ATP7B gene, which causes a buildup of copper in the body. This buildup of copper can lead to severe health problems such as cirrhosis of the liver, cognitive deficits, and eye disorders like Kayser-Fleischer rings. Symptoms often appear before adulthood, typically between ages 6 and 20. Common symptoms can include fatigue, lack of appetite, abdominal pain, jaundice, forgetfulness, speech difficulty, muscle spasms, difficulty controlling hand movement, and abnormal behavior. In later stages, Wilson's Disease may affect the brain, brain stems, and neurological systems, leading to more serious symptoms such as tremors, difficulty swallowing, seizures, and liver failure. Treatment for Wilson's Disease is aimed at reducing copper levels in the body and protecting organs from damage caused by the buildup of copper. Establishing a lifelong, comprehensive treatment plan is important for people with Wilson's Disease, as is regular monitoring of copper levels.
Ken Ware
NeuroPhysics Therapy Institute and Research Centre, Australia
Yong Xiao Wang
Albany Medical College, United States
Joe Sam Robinson
Mercer University, United States
Daniel Curry
Texas Children’s Hospital, United States
Steven Benvenisti
Davis, Saperstein Salomon, PC, United States
Andrzej Stanislaw Cieplak
Independent researcher, United States
Younok Dumortier Shin
OnusBio, United StatesSubmit your abstract Today
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States